Cirrhosis/Liver Failure News

A new type of auto-brewery syndrome was recently identified in a woman with cirrhosis and poorly controlled diabetes, according to a case report published in the Annals of Internal Medicine.

MAUI, Hawaii — To better manage alcohol-associated hepatitis, standards for the liver transplantation process should be altered as liver transplantation gains support as a therapeutic option for this disease, according to an expert at GUILD Conference 2020.

Gut microbiota analysis was cost-effective for predicting and possibly preventing 90-day readmissions for cirrhosis, according to study results.

Opioid prescriptions were associated with a risk for hepatic encephalopathy in patients with compensated cirrhosis, according to study results.

Development of chronic kidney disease following acute kidney injury in patients with cirrhosis was common and had negative impacts on relevant clinical outcomes, according to a data published in Journal of Hepatology.

Increasing care concentration for patients with cirrhosis, which was found to be less than optimal, increased mortality and health care use, according to data published in Clinical Gastroenterology and Liver Disease.

Promethera Biosciences announced the initiation of a phase 2b clinical trial to evaluate the safety and efficacy of HepaStem, a liver-derived stem cell therapy candidate for patients with acute-on-chronic liver failure, according to a press release.

The American College of Gastroenterology released a new guideline on disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries, which can lead to acute liver failure, chronic liver disease, noncirrhotic portal hypertension, cirrhosis, and hepatocellular carcinoma.

Most veteran with cirrhosis and coexisting alcohol-use disorder did not receive behavioral or pharmacotherapy treatment for alcohol use during 6 months of follow-up, according to data published in Hepatology.

Treatment with Doptelet was cost-effective for the treatment of thrombocytopenia in patients with chronic liver diseases compared with other treatment options, according to data presented at the American Society of Hematology meeting.